Literature DB >> 29285201

Effects of HuR downregulation on anaplastic thyroid cancer cells.

Lorenzo Allegri1, Catia Mio1, Diego Russo2, Sebastiano Filetti3, Federica Baldan3.   

Abstract

Anaplastic thyroid cancer (ATC) constitutes one of the most aggressive types of human solid cancer, and is characterized by the absence of thyroid differentiation features and a marked degree of invasiveness. We have previously demonstrated that the RNA-binding protein Hu antigen R (HuR) is overexpressed in thyroid carcinoma; thus, the biological role of this RNA-binding protein was investigated in the present study using the ATC cell lines SW1736 and 8505C. In both cell lines, HuR protein levels were higher compared with in the non-tumorigenic thyroid cell line Nthy-ori-3.1. HuR silencing by RNA interference in both ATC cell lines decreased cell viability, increased apoptosis rates and reduced the capability to form colonies in soft agar. Thus, HuR plays an important role in the proliferation and aggressiveness of ATC cells. The histone deacetylase inhibitor suberoylanilide hydroxamic acid (SAHA) was able to reduce the viability of ATC cells. The results demonstrated that SAHA was able to decrease HuR expression in SW1736 and 8505C cells. Furthermore, since it is known that the transcription factor nuclear factor (NF)-κB modulates HuR expression, whether SAHA affects the nuclear (active) fraction of NF-κB in ATC cells was investigated. The data suggested that SAHA decreases ATC cell viability by reducing the active form of NF-κB, which, in turn, modulates HuR expression.

Entities:  

Keywords:  HuR; RNA-binding proteins; SAHA; anaplastic thyroid cancer; siRNA

Year:  2017        PMID: 29285201      PMCID: PMC5738688          DOI: 10.3892/ol.2017.7289

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  21 in total

1.  Global quantification of mammalian gene expression control.

Authors:  Björn Schwanhäusser; Dorothea Busse; Na Li; Gunnar Dittmar; Johannes Schuchhardt; Jana Wolf; Wei Chen; Matthias Selbach
Journal:  Nature       Date:  2011-05-19       Impact factor: 49.962

Review 2.  Thyroid cancer.

Authors:  Amir H Lebastchi; Glenda G Callender
Journal:  Curr Probl Cancer       Date:  2014-05-14       Impact factor: 3.187

Review 3.  RNA-binding proteins, multifaceted translational regulators in cancer.

Authors:  Laurence Wurth; Fátima Gebauer
Journal:  Biochim Biophys Acta       Date:  2014-10-12

4.  Differential expression and localization of the mRNA binding proteins, AU-rich element mRNA binding protein (AUF1) and Hu antigen R (HuR), in neoplastic lung tissue.

Authors:  B C Blaxall; L D Dwyer-Nield; A K Bauer; T J Bohlmeyer; A M Malkinson; J D Port
Journal:  Mol Carcinog       Date:  2000-06       Impact factor: 4.784

5.  FDA approval summary: vorinostat for treatment of advanced primary cutaneous T-cell lymphoma.

Authors:  Bhupinder S Mann; John R Johnson; Martin H Cohen; Robert Justice; Richard Pazdur
Journal:  Oncologist       Date:  2007-10

Review 6.  Adaptive and maladaptive expression of the mRNA regulatory protein HuR.

Authors:  Suman Govindaraju; Beth S Lee
Journal:  World J Biol Chem       Date:  2013-11-26

7.  PARP-1 cleavage fragments: signatures of cell-death proteases in neurodegeneration.

Authors:  Ganta Vijay Chaitanya; Alexander J Steven; Phanithi Prakash Babu
Journal:  Cell Commun Signal       Date:  2010-12-22       Impact factor: 5.712

8.  Versatility of RNA-Binding Proteins in Cancer.

Authors:  Laurence Wurth
Journal:  Comp Funct Genomics       Date:  2012-05-14

9.  Dissecting the expression landscape of RNA-binding proteins in human cancers.

Authors:  Bobak Kechavarzi; Sarath Chandra Janga
Journal:  Genome Biol       Date:  2014-01-10       Impact factor: 13.583

10.  Worldwide increasing incidence of thyroid cancer: update on epidemiology and risk factors.

Authors:  Gabriella Pellegriti; Francesco Frasca; Concetto Regalbuto; Sebastiano Squatrito; Riccardo Vigneri
Journal:  J Cancer Epidemiol       Date:  2013-05-07
View more
  4 in total

1.  Effects of nutraceuticals on anaplastic thyroid cancer cells.

Authors:  Lorenzo Allegri; Francesca Rosignolo; Catia Mio; Sebastiano Filetti; Federica Baldan; Giuseppe Damante
Journal:  J Cancer Res Clin Oncol       Date:  2017-12-02       Impact factor: 4.553

2.  The HuR CMLD-2 inhibitor exhibits antitumor effects via MAD2 downregulation in thyroid cancer cells.

Authors:  Lorenzo Allegri; Federica Baldan; Sudeshna Roy; Jeffrey Aubé; Diego Russo; Sebastiano Filetti; Giuseppe Damante
Journal:  Sci Rep       Date:  2019-05-14       Impact factor: 4.996

3.  MicroRNA-139-3p Inhibits The Growth And Metastasis Of Ovarian Cancer By Inhibiting ELAVL1.

Authors:  Fang Xue; Qi Rong Li; Yan Hua Xu; Hai Bin Zhou
Journal:  Onco Targets Ther       Date:  2019-11-05       Impact factor: 4.345

4.  Role of m6A RNA Methylation in Thyroid Cancer Cell Lines.

Authors:  Lorenzo Allegri; Federica Baldan; Elisabetta Molteni; Catia Mio; Giuseppe Damante
Journal:  Int J Mol Sci       Date:  2022-09-29       Impact factor: 6.208

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.